Observational studyJournal of the American Heart Association2016
Role for Galectin-3 in Calcific Aortic Valve Stenosis.
Observational study in Journal of the American Heart Association, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Preprocedural circulating galectin-3 and the risk of mortality after transcatheter aortic valve replacement: a systematic review and meta-analysis.Bioscience reports · 2020Pooled it
- Moderate aortic stenosis: diagnostic pitfalls and the role of multimodality imaging in risk stratification and clinical management.Cardiovascular ultrasound · 2026Review
- Spatial and Single-Cell Mapping Reveals Valvular Interstitial Cell and Macrophage Sex Differences in Calcific Aortic Valve Disease.Arteriosclerosis, thrombosis, and vascular biology · 2026Article
- Integrated biomarker landscape for the early detection and management of calcific aortic valve disease.European journal of clinical investigation · 2026Review
- Dual transcriptomic profiling ofmBio · 2025Article
- Mediating effect of vascular calcification in galectin-3-related mortality in hemodialysis patients.Scientific reports · 2024Article
- Sex-specific role of galectin-3 in aortic stenosis.Biology of sex differences · 2023Article
- Influence of diabetes mellitus on the pathological profile of aortic stenosis: a sex-based approach.Cardiovascular diabetology · 2023Article
- Value of NT-proBNP and Galectin-3 as Biomarkers in the Follow-Up of Asymptomatic Elderly Patients with Severe Aortic Stenosis.Journal of clinical medicine · 2023Article
- Cellular-scale sex differences in extracellular matrix remodeling by valvular interstitial cells.Heart and vessels · 2023Article
- Sex-dependent expression of neutrophil gelatinase-associated lipocalin in aortic stenosis.Biology of sex differences · 2022Article
- Targeting Fatty Acid-Binding Protein 4 Improves Pathologic Features of Aortic Stenosis.International journal of molecular sciences · 2022Article
- Serum and Vascular Stiffness Biomarkers Associated with the Severity of Degenerative Aortic Valve Stenosis and Cardiovascular Outcomes.Journal of cardiovascular development and disease · 2022Article
- Severe Aortic Valve Stenosis and Pulmonary Hypertension: A Systematic Review of Non-Invasive Ways of Risk Stratification, Especially in Patients Undergoing Transcatheter Aortic Valve Replacement.Journal of personalized medicine · 2022Review
- Galectin-3 promotes calcification of human aortic valve interstitial cells via the NF-kappa B signaling pathway.Cardiovascular diagnosis and therapy · 2022Article
- Characterization of the sex-specific pattern of angiogenesis and lymphangiogenesis in aortic stenosis.Frontiers in cardiovascular medicine · 2022Article
- Sex-Differences in Aortic Stenosis: Mechanistic Insights and Clinical Implications.Frontiers in cardiovascular medicine · 2022Article
- Can Blood-Circulating Factors Unveil and Delay Your Biological Aging?Biomedicines · 2020Review
- Bone mineral density and mortality in end-stage renal disease patients.Clinical kidney journal · 2020Review
- Pleiotropic Effects of Modified Citrus Pectin.Nutrients · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAortic stenosis (AS) is a chronic inflammatory disease, and calcification plays an important role in the progression of the disease. Galectin-3 (Gal-3) is a proinflammatory molecule involved in vascular osteogenesis in atherosclerosis. Therefore, we hypothesized that Gal-3 could mediate valve calcification in AS. METHODS AND
resultsBlood samples and aortic valves (AVs) from 77 patients undergoing AV replacement were analyzed. As controls, noncalcified human AVs were obtained at autopsy (n=11). Gal-3 was spontaneously expressed in valvular interstitial cells (VICs) from AVs and increased in AS as compared to control AVs. Positive correlations were found between circulating and valvular Gal-3 levels. Valvular Gal-3 colocalized with the VICs markers, alpha-smooth muscle actin and vimentin, and with the osteogenic markers, osteopontin, bone morphogenetic protein 2, runt-related transcription factor 2, and SRY (sex-determining region Y)-box 9. Gal-3 also colocalized with the inflammatory markers cd68, cd80 and tumor necrosis factor alpha. In vitro, in VICs isolated from AVs, Gal-3 induced expression of inflammatory, fibrotic, and osteogenic markers through the extracellular signal-regulated kinase 1 and 2 pathway. Gal-3 expression was blocked in VICs undergoing osteoblastic differentiation using its pharmacological inhibitor, modified citrus pectin, or the clustered regularly interspaced short palindromic repeats/Cas9 knockout system. Gal-3 blockade and knockdown decreased the expression of inflammatory, fibrotic, and osteogenic markers in differentiated VICs.
conclusionsGal-3, which is overexpressed in AVs from AS patients, appears to play a central role in calcification in AS. Gal-3 could be a new therapeutic approach to delay the progression of AV calcification in AS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.